Sucampo Pharma (SCMP) Tops Q3 EPS by 2c, Guidance Beats

November 9, 2016 8:38 AM EST

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Sucampo Pharma (NASDAQ: SCMP) reported Q3 EPS of $0.28, $0.02 better than the analyst estimate of $0.26. Revenue for the quarter came in at $57.9 million versus the consensus estimate of $51.46 million.


Sucampo Pharma sees FY2016 EPS of $1.20-$1.25, versus the consensus of $1.04. Sucampo Pharma sees FY2016 revenue of $220-225 million, versus the consensus of $205.7 million.

For earnings history and earnings-related data on Sucampo Pharma (SCMP) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Earnings, Guidance

Related Entities


Add Your Comment